Our Pricing

Is Wegovy Safer Than Mounjaro? A UK Pharmacist's Clinical Comparison

When patients ask is Wegovy safer than Mounjaro, they're comparing two of the most effective weight loss injections licensed in the UK. Both semaglutide (Wegovy) and tirzepatide (Mounjaro) demonstrate excellent safety profiles in clinical trials, but their side effect patterns, contraindications, and long-term safety data differ in clinically meaningful ways. As a UK registered pharmacist who has supported thousands of patients through weight loss treatment, I'll provide a transparent, evidence-based comparison to help you make an informed decision with your prescriber.

Is Wegovy Safer Than Mounjaro? Understanding the Core Safety Question

The question of whether Wegovy is safer than Mounjaro cannot be answered with a simple yes or no, because safety is multifaceted and depends on your individual medical history, risk factors, and treatment goals. Both medications are GLP-1 receptor agonists approved by the MHRA for chronic weight management in adults with obesity or overweight with weight-related comorbidities, and both underwent rigorous clinical trials demonstrating acceptable safety profiles [1].

Wegovy (semaglutide 2.4mg weekly) has been available longer globally, with extensive real-world safety data accumulated since its approval. The STEP clinical trial programme enrolled over 4,500 participants and tracked adverse events systematically [2]. Mounjaro (tirzepatide) is a dual GIP/GLP-1 receptor agonist with a slightly different mechanism, studied in the SURMOUNT trials involving over 5,000 participants [3]. Both trials showed similar discontinuation rates due to adverse events — approximately 4-7% — suggesting comparable overall tolerability when properly titrated.

The most common side effects for both medications are gastrointestinal: nausea, diarrhoea, vomiting, and constipation. In head-to-head comparisons of trial data, Mounjaro appears to cause slightly higher rates of nausea and vomiting during dose escalation, particularly at the higher maintenance doses (10mg and 15mg), while Wegovy's side effect profile remains more consistent across its single maintenance dose of 2.4mg [1][3]. However, individual tolerance varies significantly, and many patients experience minimal or no gastrointestinal symptoms with either treatment when following the recommended dose escalation schedule.

Comparing Side Effect Profiles: Is Wegovy Safer Than Mounjaro for Gastrointestinal Tolerance?

Gastrointestinal side effects are the primary reason patients discontinue GLP-1 receptor agonists, making this comparison central to the safety question. In the STEP trials, approximately 44% of Wegovy users reported nausea, compared to 5% on placebo, with most cases being mild to moderate and resolving within the first 8-12 weeks [2]. The SURMOUNT-1 trial reported nausea in 33-39% of tirzepatide users depending on dose, but vomiting was notably more common at higher Mounjaro doses (10-15mg) compared to Wegovy's single 2.4mg dose [3].

From a clinical perspective, the key difference is dose flexibility. Mounjaro offers multiple maintenance doses (5mg, 7.5mg, 10mg, 12.5mg, 15mg), allowing prescribers to optimise the balance between efficacy and tolerability for each patient. Wegovy has a fixed 2.4mg maintenance dose, which may be ideal for some but too aggressive for others. If you're particularly sensitive to gastrointestinal side effects, starting with Mounjaro and remaining at a lower maintenance dose (5mg or 7.5mg) may provide better tolerability, though potentially with slightly less weight loss compared to the maximum doses.

Both medications carry warnings for acute pancreatitis, gallbladder disease, and potential thyroid C-cell tumours (based on rodent studies, not confirmed in humans). The incidence of pancreatitis in clinical trials was rare for both — less than 0.2% — and similar between Wegovy and Mounjaro [1][3]. Neither medication is definitively safer regarding these serious but uncommon risks, and both require the same clinical vigilance and patient education about warning symptoms.

Cardiovascular Safety: A Crucial Consideration

Wegovy has published cardiovascular outcomes trial data (the SELECT trial) demonstrating a 20% reduction in major adverse cardiovascular events in adults with established cardiovascular disease and obesity [4]. This represents a significant safety advantage for patients with existing heart disease, as Wegovy is not only safe in this population but actively protective. Mounjaro's cardiovascular outcomes trial (SURPASS-CVOT) is ongoing, with results expected in 2024-2025, so we cannot yet make the same evidence-based claim for tirzepatide in high-risk cardiovascular patients.

For patients without established cardiovascular disease, both medications show favourable effects on cardiovascular risk factors — reducing blood pressure, improving lipid profiles, and enhancing glycaemic control in those with prediabetes or type 2 diabetes. There is no evidence suggesting either medication increases cardiovascular risk in this population, but Wegovy currently holds the advantage of proven cardiovascular benefit in the highest-risk group.

Is Wegovy Safer Than Mounjaro for Patients with Specific Medical Conditions?

Safety is highly individualised, and certain medical conditions may make one medication preferable over the other. Both Wegovy and Mounjaro are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), and both require caution in patients with a history of pancreatitis [1][3].

For patients with type 2 diabetes, Mounjaro may offer a slight safety advantage due to its dual GIP/GLP-1 mechanism, which appears to cause less hypoglycaemia when used alongside other diabetes medications compared to GLP-1 agonists alone. However, Wegovy is not licensed for diabetes treatment in the UK — it is specifically indicated for weight management — so this comparison is only relevant if you're using these medications off-label or switching from diabetes formulations.

Patients with severe gastroparesis (delayed stomach emptying) should approach both medications with caution, as GLP-1 receptor agonists slow gastric emptying as part of their mechanism. There is no clear evidence that Wegovy is safer than Mounjaro in this regard, and both require careful prescriber assessment. Similarly, both medications require dose adjustment consideration in patients with renal impairment, though neither is contraindicated in mild to moderate kidney disease.

Pregnancy, Breastfeeding, and Fertility Considerations

Both Wegovy and Mounjaro are contraindicated in pregnancy due to potential risks to the developing foetus observed in animal studies. Women of childbearing potential must use effective contraception during treatment and discontinue the medication at least 2 months before a planned pregnancy (for Wegovy) or 4 weeks (for Mounjaro based on its shorter half-life). Neither medication has demonstrated safety in breastfeeding, and both should be avoided while nursing.

Importantly, weight loss itself can increase fertility in women with obesity-related anovulation, so patients using either medication should be counselled about the increased possibility of pregnancy and the critical importance of reliable contraception throughout treatment.

Long-Term Safety Data: Is Wegovy Safer Than Mounjaro Over Extended Use?

Wegovy benefits from a longer track record of real-world use, as semaglutide has been available for type 2 diabetes (as Ozempic) since 2017 and for weight management (as Wegovy) since 2021 in the US and 2023 in the UK. This extended observation period has not revealed unexpected long-term safety signals, and the medication continues to demonstrate a favourable benefit-risk profile in post-marketing surveillance [2][4].

Mounjaro (tirzepatide) is newer, approved for weight management in the UK in 2023, though it has been used for type 2 diabetes since 2022. While the SURMOUNT trials included treatment periods up to 72 weeks, we have less real-world data on very long-term use (beyond 2-3 years) compared to Wegovy. This does not mean Mounjaro is less safe — the available data is reassuring — but Wegovy's longer observation window provides greater confidence in the absence of delayed or rare adverse effects.

Both medications are intended for chronic, ongoing use rather than short-term treatment, as weight regain is common after discontinuation. The decision about which is safer for long-term use should incorporate your prescriber's clinical judgement, your individual response and tolerability, and ongoing monitoring of weight, metabolic parameters, and any emerging side effects.

Cost, Accessibility, and Practical Safety: Is Wegovy Safer Than Mounjaro in Real-World UK Use?

Practical safety extends beyond clinical trial data to include medication accessibility, adherence support, and cost-related treatment interruptions. At Cured Pharmacy, Wegovy is available from £124.99 per month subject to prescriber approval, representing competitive UK pricing that supports consistent, uninterrupted treatment — a critical factor in both safety and efficacy. Treatment interruptions due to cost can lead to rebound weight gain and the need to restart dose titration, potentially increasing side effect burden.

Both medications require proper injection technique training, safe needle disposal, and refrigerated storage until first use. The pen devices for both Wegovy and Mounjaro are designed for ease of use, with similar safety profiles regarding injection site reactions (mild, occurring in less than 2% of users). Neither medication has a meaningful safety advantage regarding administration technique or device-related risks.

Adherence is a safety factor often overlooked in clinical comparisons. Missing doses or inconsistent use can lead to erratic blood levels, increased side effects when resuming, and suboptimal outcomes. Wegovy's once-weekly dosing matches Mounjaro's schedule, so both offer equivalent convenience. The choice between them should be based on individual tolerability, prescriber recommendation, and sustainable access to ongoing treatment rather than dosing frequency.

Monitoring Requirements and Safety Protocols

Both Wegovy and Mounjaro require the same baseline and ongoing monitoring: assessment of renal function, lipid profile, HbA1c (if diabetic or prediabetic), and clinical review of gastrointestinal symptoms, injection site reactions, and overall tolerability. Your prescriber should arrange follow-up consultations at regular intervals — typically every 3-6 months — to assess treatment response, adjust doses if needed, and screen for any emerging safety concerns.

At Cured Pharmacy, all patients undergo a thorough online clinical assessment by a UK-registered prescriber before treatment initiation, with ongoing support from our clinical team led by Superintendent Pharmacist Tarun Kumar (GPhC 2233073). This structured monitoring approach ensures both Wegovy and Mounjaro are prescribed safely, with individualised risk-benefit evaluation rather than a one-size-fits-all approach.

Final Verdict: Is Wegovy Safer Than Mounjaro for Your Individual Situation?

After reviewing the clinical trial data, real-world evidence, and practical considerations, the answer to whether Wegovy is safer than Mounjaro is: both medications demonstrate excellent safety profiles, and neither is categorically safer for all patients. The optimal choice depends on your individual medical history, cardiovascular risk, gastrointestinal sensitivity, treatment goals, and response to therapy.

Wegovy may be the safer choice if you have established cardiovascular disease (due to proven cardiovascular benefit in the SELECT trial), prefer a medication with longer real-world safety data, or respond well to a fixed-dose regimen. Mounjaro may be preferable if you benefit from dose flexibility to optimise tolerability, have type 2 diabetes requiring robust glycaemic control, or experience better gastrointestinal tolerance at lower tirzepatide doses compared to semaglutide.

The most important safety factor is working with a qualified UK prescriber who can assess your full medical history, discuss your preferences and concerns, and provide ongoing monitoring throughout treatment. Both medications require prescription-only access following clinical assessment, ensuring that safety is individually evaluated rather than assumed. At Cured Pharmacy, our clinical team provides this personalised approach, with transparent pricing from £124.99 for Wegovy, supporting safe, accessible, and effective weight management treatment across the UK.

Scientific References

1. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., ... & Kushner, R. F. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. [accessed 15 August 2026]
2. Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., ... & Wadden, T. A. (2021). Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA, 325(14), 1414-1425. [accessed 15 August 2026]
3. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., ... & Bunck, M. C. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216. [accessed 15 August 2026]
4. Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., ... & Ryan, D. H. (2023). Semaglutide and cardiovascular outcomes in obesity without diabetes. New England Journal of Medicine, 389(24), 2221-2232. [accessed 15 August 2026]
5. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 15 August 2026.
6. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 15 August 2026.
7. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 15 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.